HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

RIBOLIFE-B

56.450

-1.250-2.17%

Volume:391.60K

Turnover:22.38M

Market Cap:9.60B

PE:-26.88

High:59.450

Open:57.900

Low:56.300

Close:57.700

52wk High:95.800

52wk Low:43.600

Shares:170.00M

HK Float Shares:170.00M

Volume Ratio:0.57

T/O Rate:0.23%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-2.100

ROE:-17.59%

ROA:-3.85%

PB:4.74

PE(LYR):-26.88

PS:17.67

Loading ...

Overview Company News Filings

RIBOLIFE-B Repurchases 16,600 Shares for HK$958,700 on September 8

Suzhou Ribo Files HKEX Next-Day Disclosure Return on Share Repurchase Cancellation

Suzhou Ribo Life Science Joins Hang Seng Composite Index##

RIBOLIFE-B Monthly Return: Share Capital Steady at RMB 170.55 Million, No New Issuance in August 2026

Bulletin Express

RIBOLIFE-B Surges Over 4% in Morning Trade as Mid-Year Net Profit Turns Positive at RMB 23 Million

RIBOLIFE-B (06938) 2026 Interim Results: Global Partnerships Fuel Revenue Surge While Core Pipelines and Platform Value Continue to Unlock

RIBOLIFE-B Swings to Profit on 304% Revenue Surge, Driven by Licensing Deals

Bulletin Express

Suzhou Ribo Life Science Swings to FY26 H1 Profit of RMB 23.45 Million; Revenue Rises to RMB 419.74 Million

Hong Kong Stock Market Movers | RIBOLIFE-B (06938) Surges Over 9% on Hang Seng Composite Index Inclusion, First-Half Revenue Expected to Rise Up to 3.2-Fold

Ribo Life Science Sets 27 Aug 2026 Board Meeting to Approve 1H26 Results and Consider Interim Dividend

Bulletin Express

Suzhou Ribo Life Science Board Meets to Review Interim Results, Consider Dividend

Suzhou Ribo Life Science Expects Revenue of Rmb311 Million-RMB436 Million for Six Months

Suzhou Ribo Life Science Co - Expected Hy Revenue Growth Mainly Driven by Madrigal Pharmaceuticals and Boehringer Ingelheim Collaborations

THOMSON REUTERS

Ribo Life Science Secures EMA Approval to Launch Phase 2b MRCT of siRNA Candidate Vortosiran for AF-Related Stroke Prevention

Bulletin Express

Suzhou Ribo Life Science Co - Ema Approves Initiation of Phase 2B Trial of Vortosiran for Spaf

THOMSON REUTERS

Suzhou Ribo Wins EMA Approval for Phase 2b Vortosiran Trial in Stroke Prevention for Atrial Fibrillation

RIBOLIFE-B Buys Back Shares for HK$4.22 Million

Suzhou Ribo Files HKEX Next-day Disclosure Return on Share Repurchase Cancellation

Ribo Discloses Positive Data from Vortosiran Phase 2a Trial - World's First Clinical Data on Sirna-mediated Fxi Inhibition Following Multiple Dosing in Patients with Coronary Artery Disease

THOMSON REUTERS

Suzhou Ribo Life Science Co - no Serious Adverse or Major Bleeding Events Observed in Vortosiran Phase 2a Trial

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigreclipse.com/stock/06938/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"06938","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"06938\",,,,,undefined,":{"symbol":"06938","market":"HK","secType":"STK","nameCN":"RIBOLIFE-B","latestPrice":56.45,"timestamp":1789027722334,"preClose":57.7,"halted":0,"volume":391600,"delay":0,"changeRate":-0.02166377816291161,"floatShares":170000000,"shares":170000000,"eps":-2.100221,"marketStatus":"Closed","change":-1.25,"latestTime":"09-10 16:08:42","open":57.9,"high":59.45,"low":56.3,"amount":22380100,"amplitude":0.054593,"askPrice":56.6,"askSize":200,"bidPrice":56.45,"bidSize":200,"shortable":0,"etf":0,"ttmEps":-1.149,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1789090200000},"marketStatusCode":5,"adr":0,"listingDate":1767888000000,"exchange":"SEHK","adjPreClose":57.7,"openAndCloseTimeList":[[1789003800000,1789012800000],[1789016400000,1789027200000]],"volumeRatio":0.571824,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"06938\",,,,,undefined,":{"symbol":"06938","floatShares":170000000,"roa":"-3.85%","roe":"-17.59%","lyrEps":-2.100221,"volumeRatio":0.571824,"shares":170000000,"dividePrice":0,"high":59.45,"amplitude":0.054593,"preClose":57.7,"low":56.3,"week52Low":43.6,"pbRate":"4.74","psRate":"17.67","week52High":95.8,"institutionHeld":0,"latestPrice":56.45,"eps":-2.100221,"divideRate":0,"volume":391600,"delay":0,"ttmEps":-1.149,"open":57.9,"prevYearClose":57.97,"prevWeekClose":66.05,"prevMonthClose":60.25,"prevQuarterClose":46.9,"fiveDayClose":64.25,"twentyDayClose":54,"sixtyDayClose":50.8},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/06938\",params:#limit:5,,,undefined,":[{"date":"2026-08-27","symbol":"06938","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787794200000,"name":null,"time":"","dateTimestamp":1787760000000,"actualEps":null},{"market":"HK","date":"2026-03-25","symbol":"06938","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1774368000000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"06938\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"06938\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.75,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.75,"analysts":8,"updateTime":1784304000000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/06938\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"06938","date":"2026-09-09","current":-49.129678,"percent":0.065217,"low":-56.914635,"twenty":-39.334312,"median":-30.985978,"eighty":-26.650283,"high":-23.913403,"avg":-33.56676,"sd":8.013017,"marketCap":9841018307},"quantilePoints":[{"date":"2026-02-13","current":-47.784644,"twenty":-49.967526,"median":-49.148945,"eighty":-48.330365,"marketCap":11947371445},{"date":"2026-02-20","current":-49.493094,"twenty":-49.901155,"median":-49.02522,"eighty":-48.248265,"marketCap":12356703229},{"date":"2026-02-27","current":-46.28708,"twenty":-49.778496,"median":-48.557346,"eighty":-47.185619,"marketCap":11683011335},{"date":"2026-03-06","current":-41.043234,"twenty":-48.963884,"median":-47.035862,"eighty":-41.420692,"marketCap":10275933327},{"date":"2026-03-13","current":-37.939269,"twenty":-48.578839,"median":-43.677981,"eighty":-39.627323,"marketCap":9542547214},{"date":"2026-03-20","current":-38.832211,"twenty":-48.543939,"median":-40.85279,"eighty":-39.405242,"marketCap":9730157615},{"date":"2026-03-27","current":-30.985978,"twenty":-48.084787,"median":-40.112534,"eighty":-38.372934,"marketCap":9755740852},{"date":"2026-04-02","current":-34.881193,"twenty":-47.185618,"median":-39.757485,"eighty":-36.526858,"marketCap":11034902677},{"date":"2026-04-10","current":-37.770699,"twenty":-46.28708,"median":-39.613953,"eighty":-36.479378,"marketCap":12041176646},{"date":"2026-04-17","current":-35.241421,"twenty":-45.408639,"median":-38.832211,"eighty":-35.918978,"marketCap":11239568569},{"date":"2026-04-24","current":-33.421304,"twenty":-43.677981,"median":-38.300657,"eighty":-35.241421,"marketCap":10659681875},{"date":"2026-04-30","current":-32.557368,"twenty":-42.07346,"median":-37.836456,"eighty":-34.614071,"marketCap":10386794019},{"date":"2026-05-08","current":-32.498031,"twenty":-41.169053,"median":-37.354591,"eighty":-33.058756,"marketCap":10403849510},{"date":"2026-05-15","current":-32.120533,"twenty":-40.738524,"median":-36.586666,"eighty":-32.493391,"marketCap":10310044309},{"date":"2026-05-22","current":-30.090442,"twenty":-40.591323,"median":-35.918978,"eighty":-32.095834,"marketCap":9636352415},{"date":"2026-05-29","current":-30.88841,"twenty":-40.296947,"median":-35.448939,"eighty":-31.691849,"marketCap":9926295762},{"date":"2026-06-05","current":-28.193848,"twenty":-40.051892,"median":-35.061307,"eighty":-30.899503,"marketCap":9073521212},{"date":"2026-06-12","current":-27.046231,"twenty":-39.859077,"median":-34.61525,"eighty":-30.390832,"marketCap":8698300410},{"date":"2026-06-18","current":-26.187923,"twenty":-39.726813,"median":-33.720381,"eighty":-29.853022,"marketCap":8442468045},{"date":"2026-06-26","current":-23.913403,"twenty":-39.627323,"median":-32.945231,"eighty":-29.564677,"marketCap":7671559851},{"date":"2026-07-03","current":-27.120201,"twenty":-39.476172,"median":-32.527699,"eighty":-28.324896,"marketCap":8706828155},{"date":"2026-07-10","current":-25.658884,"twenty":-39.120404,"median":-32.474833,"eighty":-27.529192,"marketCap":8227568858},{"date":"2026-07-17","current":-25.917703,"twenty":-38.802803,"median":-32.09845,"eighty":-26.657872,"marketCap":8340135099},{"date":"2026-07-24","current":-28.402389,"twenty":-38.680546,"median":-32.07594,"eighty":-26.891702,"marketCap":9141743176},{"date":"2026-07-31","current":-24.94248,"twenty":-38.662044,"median":-31.566896,"eighty":-26.553964,"marketCap":8043369555},{"date":"2026-08-07","current":-27.580979,"twenty":-37.939269,"median":-30.913769,"eighty":-26.515913,"marketCap":8911494047},{"date":"2026-08-14","current":-27.888785,"twenty":-37.902214,"median":-30.842167,"eighty":-26.553964,"marketCap":9022354739},{"date":"2026-08-21","current":-28.090305,"twenty":-37.770699,"median":-30.35874,"eighty":-26.553964,"marketCap":9107632194},{"date":"2026-08-28","current":-53.27383,"twenty":-37.770699,"median":-30.842167,"eighty":-26.562391,"marketCap":10540293438},{"date":"2026-09-04","current":-56.914635,"twenty":-38.685171,"median":-30.913769,"eighty":-26.600296,"marketCap":11265151805},{"date":"2026-09-09","current":-49.640073,"twenty":-39.334312,"median":-30.985978,"eighty":-26.650283,"marketCap":9841018307}],"updateTime":1789030306401},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"06938\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1140910876","title":"RIBOLIFE-B Repurchases 16,600 Shares for HK$958,700 on September 8","url":"https://stock-news.laohu8.com/highlight/detail?id=1140910876","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1140910876?lang=en_us&edition=fundamental","pubTime":"2026-09-08 19:46","pubTimestamp":1788867973,"startTime":"0","endTime":"0","summary":"RIBOLIFE-B (06938) announced that on September 8, 2026, it repurchased 16,600 shares at a total cost of HK$958,700.This buyback reflects the company's ongoing capital management strategy, utilizing its cash reserves to return value to shareholders.","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665327282","title":"Suzhou Ribo Files HKEX Next-Day Disclosure Return on Share Repurchase Cancellation","url":"https://stock-news.laohu8.com/highlight/detail?id=2665327282","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665327282?lang=en_us&edition=fundamental","pubTime":"2026-09-08 19:43","pubTimestamp":1788867791,"startTime":"0","endTime":"0","summary":"Suzhou Ribo files HKEX next-day disclosure return on share repurchase cancellationSuzhou Ribo Life Science repurchased 16,600 H shares on Sept. 8 for treasury, per its HKEX next-day disclosure return.Buyback price HKD 57.75 per share. Total consideration HKD 958,650.Shares repurchased for cancellation: 0.Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Suzhou Ribo Life Science Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange  , on September 08, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nNDL1MwzRw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665439981","title":"Suzhou Ribo Life Science Joins Hang Seng Composite Index##","url":"https://stock-news.laohu8.com/highlight/detail?id=2665439981","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665439981?lang=en_us&edition=fundamental","pubTime":"2026-09-07 12:13","pubTimestamp":1788754415,"startTime":"0","endTime":"0","summary":"Suzhou Ribo Life Science joins Hang Seng Composite Index##Suzhou Ribo Life Science will be added to the Hang Seng Composite Index, effective Sept. 7, 2026.The stock will also enter the Southbound Trad","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260907:nNDL9L1FL3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114850407","title":"RIBOLIFE-B Monthly Return: Share Capital Steady at RMB 170.55 Million, No New Issuance in August 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1114850407","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1114850407?lang=en_us&edition=fundamental","pubTime":"2026-09-04 18:22","pubTimestamp":1788517356,"startTime":"0","endTime":"0","summary":"Suzhou Ribo Life Science Co., Ltd. (RIBOLIFE-B) reported no changes in its equity structure for the month ended 31 August 2026, according to the company’s monthly return filed with Hong Kong...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156963993","title":"RIBOLIFE-B Surges Over 4% in Morning Trade as Mid-Year Net Profit Turns Positive at RMB 23 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1156963993","media":"Deep News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1156963993?lang=en_us&edition=fundamental","pubTime":"2026-09-02 11:10","pubTimestamp":1788318619,"startTime":"0","endTime":"0","summary":"Shares of RIBOLIFE-B (06938) climbed as much as 5% during the trading session, with the stock last up 3.73% at HK$62.60, reflecting a turnover of approximately HK$11.08 million. The company recently...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170677910","title":"RIBOLIFE-B (06938) 2026 Interim Results: Global Partnerships Fuel Revenue Surge While Core Pipelines and Platform Value Continue to Unlock","url":"https://stock-news.laohu8.com/highlight/detail?id=1170677910","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1170677910?lang=en_us&edition=fundamental","pubTime":"2026-08-28 08:48","pubTimestamp":1787878112,"startTime":"0","endTime":"0","summary":"On August 27, RIBOLIFE-B (06938) released its 2026 interim results. The recent explosive growth in the global oligonucleotide therapeutics market and the continuous breakthroughs in industry...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107996237","title":"RIBOLIFE-B Swings to Profit on 304% Revenue Surge, Driven by Licensing Deals","url":"https://stock-news.laohu8.com/highlight/detail?id=1107996237","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1107996237?lang=en_us&edition=fundamental","pubTime":"2026-08-27 19:43","pubTimestamp":1787831014,"startTime":"0","endTime":"0","summary":"Suzhou Ribo Life Science Co., Ltd. (RIBOLIFE-B, 06938) reported a sharp turnaround for 1H 2026, underpinned by upfront and milestone payments from global partners Madrigal Pharmaceuticals and...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"RIBOLIFE-B Swings to Profit on 304% Revenue Surge, Driven by Licensing Deals","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662090767","title":"Suzhou Ribo Life Science Swings to FY26 H1 Profit of RMB 23.45 Million; Revenue Rises to RMB 419.74 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2662090767","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662090767?lang=en_us&edition=fundamental","pubTime":"2026-08-27 19:14","pubTimestamp":1787829268,"startTime":"0","endTime":"0","summary":"Suzhou Ribo Life Science swings to FY26 H1 profit of RMB 23.45 million; revenue rises to RMB 419.74 millionSuzhou Ribo Life Science posted revenue of RMB 419.7 million, up 304.3% year over year.Profit","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nNDL69kLR8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102363568","title":"Hong Kong Stock Market Movers | RIBOLIFE-B (06938) Surges Over 9% on Hang Seng Composite Index Inclusion, First-Half Revenue Expected to Rise Up to 3.2-Fold","url":"https://stock-news.laohu8.com/highlight/detail?id=1102363568","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1102363568?lang=en_us&edition=fundamental","pubTime":"2026-08-24 11:32","pubTimestamp":1787542351,"startTime":"0","endTime":"0","summary":"Shares of RIBOLIFE-B (06938) jumped more than 9% in early trading, last up 8.9% at HK$58.15 with turnover reaching HK$32.03 million.On the news front, Hang Seng Indexes Company announced its...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KCAI","VXUS","BK4585","BK4588","06938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140772281","title":"Ribo Life Science Sets 27 Aug 2026 Board Meeting to Approve 1H26 Results and Consider Interim Dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=1140772281","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1140772281?lang=en_us&edition=fundamental","pubTime":"2026-08-17 17:06","pubTimestamp":1786957617,"startTime":"0","endTime":"0","summary":"Ribo Life Science has scheduled a board meeting for Thursday, 27 August 2026. Directors will review and approve the unaudited results for the six months ended 30 June 2026, decide on the timing of...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660870485","title":"Suzhou Ribo Life Science Board Meets to Review Interim Results, Consider Dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=2660870485","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660870485?lang=en_us&edition=fundamental","pubTime":"2026-08-17 16:45","pubTimestamp":1786956331,"startTime":"0","endTime":"0","summary":"Suzhou Ribo Life Science board meets to review interim results, consider dividendAug. 27, 2026: Suzhou Ribo Life Science board meeting to review interim results for the six months ended June 30, 2026.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nNDL7pnh1S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655627148","title":"Suzhou Ribo Life Science Expects Revenue of Rmb311 Million-RMB436 Million for Six Months","url":"https://stock-news.laohu8.com/highlight/detail?id=2655627148","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655627148?lang=en_us&edition=fundamental","pubTime":"2026-07-29 19:35","pubTimestamp":1785324940,"startTime":"0","endTime":"0","summary":"BRIEF-Suzhou Ribo Life Science Expects Revenue Of RMB311 Million-RMB436 Million For Six MonthsJuly 29 (Reuters)-Suzhou Ribo Life Science Co Ltd6938.HK:EXPECTS REVENUE OF RMB311 MILLION-RMB436 MILLION ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260729:nFWN43V0W7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655248866","title":"Suzhou Ribo Life Science Co - Expected Hy Revenue Growth Mainly Driven by Madrigal Pharmaceuticals and Boehringer Ingelheim Collaborations","url":"https://stock-news.laohu8.com/highlight/detail?id=2655248866","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655248866?lang=en_us&edition=fundamental","pubTime":"2026-07-29 18:18","pubTimestamp":1785320283,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260729:nFWN43V0W7:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["06938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119391095","title":"Ribo Life Science Secures EMA Approval to Launch Phase 2b MRCT of siRNA Candidate Vortosiran for AF-Related Stroke Prevention","url":"https://stock-news.laohu8.com/highlight/detail?id=1119391095","media":"Bulletin Express","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1119391095?lang=en_us&edition=fundamental","pubTime":"2026-07-28 20:06","pubTimestamp":1785240379,"startTime":"0","endTime":"0","summary":"On 28 July 2026, Suzhou Ribo Life Science Co., Ltd. (Ribo Life Science) disclosed that the European Medicines Agency has authorised the initiation of ORBIT-XI-AF, a Phase 2b multi-regional clinical...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654900192","title":"Suzhou Ribo Life Science Co - Ema Approves Initiation of Phase 2B Trial of Vortosiran for Spaf","url":"https://stock-news.laohu8.com/highlight/detail?id=2654900192","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654900192?lang=en_us&edition=fundamental","pubTime":"2026-07-28 19:58","pubTimestamp":1785239934,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260728:nFWN43U15S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["06938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654001925","title":"Suzhou Ribo Wins EMA Approval for Phase 2b Vortosiran Trial in Stroke Prevention for Atrial Fibrillation","url":"https://stock-news.laohu8.com/highlight/detail?id=2654001925","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654001925?lang=en_us&edition=fundamental","pubTime":"2026-07-28 19:58","pubTimestamp":1785239929,"startTime":"0","endTime":"0","summary":"Suzhou Ribo wins EMA approval for Phase 2b vortosiran trial in stroke prevention for atrial fibrillationSuzhou Ribo Life Science secured European Medicines Agency clearance to start a Phase 2b trial o","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260728:nNDL1qmxLt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162346052","title":"RIBOLIFE-B Buys Back Shares for HK$4.22 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1162346052","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1162346052?lang=en_us&edition=fundamental","pubTime":"2026-07-24 20:44","pubTimestamp":1784897051,"startTime":"0","endTime":"0","summary":"RIBOLIFE-B (06938) announced a share buyback on July 24, 2026.The company spent approximately HK$4.2237 million to repurchase 78,400 shares.The repurchase price ranged from HK$52.6 to HK$54.4 per share.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653808262","title":"Suzhou Ribo Files HKEX Next-day Disclosure Return on Share Repurchase Cancellation","url":"https://stock-news.laohu8.com/highlight/detail?id=2653808262","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653808262?lang=en_us&edition=fundamental","pubTime":"2026-07-24 20:37","pubTimestamp":1784896639,"startTime":"0","endTime":"0","summary":"Suzhou Ribo files HKEX next-day disclosure return on share repurchase cancellationSuzhou Ribo repurchased 78,400 H shares on July 24 for treasury, no shares repurchased for cancellation.Buyback price ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260724:nNDL2ZBZxp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653750982","title":"Ribo Discloses Positive Data from Vortosiran Phase 2a Trial - World's First Clinical Data on Sirna-mediated Fxi Inhibition Following Multiple Dosing in Patients with Coronary Artery Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2653750982","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653750982?lang=en_us&edition=fundamental","pubTime":"2026-07-22 20:23","pubTimestamp":1784723004,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260722:nTUA5PZQHL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653075098","title":"Suzhou Ribo Life Science Co - no Serious Adverse or Major Bleeding Events Observed in Vortosiran Phase 2a Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2653075098","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653075098?lang=en_us&edition=fundamental","pubTime":"2026-07-22 20:23","pubTimestamp":1784723004,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260722:nTUA5PZQHL:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["06938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":1,"totalSize":92,"code":"91000000","status":"200"}]}}